Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Cost and Efficacy of Upfront Plerixafor Versus a “Just-in-Time” (JIT) Approach in Hematopoietic Progenitor Cell (HPC) Mobilization

Lauren Westfall Veltri, MD, Aaron Cumpston, PharmD, Alexandra Shillingburg, PharmD, Christopher Lipinski, Sijin Wen, PhD, Sonia Leadmon, Kathy Watkins, MT, Lab Technician, Michael David Craig, MD, Mehdi Hamadani, MD, Abraham S. Kanate, MD

Blood (2014) 124 (21): 1127.

https://doi.org/10.1182/blood.V124.21.1127.1127

Published: 2014

Journal Articles

Predictors and Impact Of 30-Day Readmissions On Patient Outcomes and Healthcare Costs After Allogeneic Hematopoietic Cell Transplantation

Abraham Sebastian Kanate, MD, Sherri Rauenzahn, MD, Sonia Leadmon, BS, Quoc V. Truong, MD, Aaron Cumpston, PharmD, Londia Goff, Kim Evans, Jianjun Zhang, Sijin Wen, Michael Craig, Mehdi Hamadani, MD

Blood (2013) 122 (21): 1718.

https://doi.org/10.1182/blood.V122.21.1718.1718

Published: 2013

Journal Articles

Intermediate-Dose Cyclophosphamide Versus Plerixafor and Granulocyte Colony Stimulating Factor (G-CSF) for Peripheral Blood Progenitor Cell (PBPC) Mobilization in Patients with Multiple Myeloma (MM) Treated with Novel Induction Chemotherapies – A Multicenter Analysis

Farrukh Awan, MD, MS, Samith Thomas Kochuparambil, Michael Craig, Aaron Cumpston, PharmD, Sonia Leadmon, BS, Kathy Watkins, David Deremer, Jeremy Pantin, MD, Vamsi Kota, MBBS, Anand P. Jillella, MD, Mehdi Hamadani, MD

Blood (2012) 120 (21): 4409.

https://doi.org/10.1182/blood.V120.21.4409.4409

Published: 2012

Journal Articles

Intermediate- Versus Low-Dose Cyclophosphamide and Granulocyte Colony Stimulating Factor for Peripheral Blood Progenitor Cell Mobilization in Patients with Multiple Myeloma Treated with Novel Induction Chemotherapies – A Multicenter Analysis

Sayed Mehdi Hamadani, MD, Thomas Samith Kochuparambil, Salman Osman, MD, Ethan Speir, Michael Craig, MD, David Deremer, Aaron Cumpston, PharmD, Devi D Morrison, Sonia Leadmon, BS, Kristen Sterling, Pamela Bunner, BS, Meghan Sterrett, Vamsi Kota, MBBS, Anand P. Jillella, MD, Farrukh T Awan, MD, MS

Blood (2011) 118 (21): 313.

https://doi.org/10.1182/blood.V118.21.313.313

Published: 2011

Journal Articles

Response to Induction Chemotherapy with Novel Agents Does Not Predict Outcomes of Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation

Salman Osman, MD, Abraham Sebastian Kanate, MD, Pamela Bunner, BS, Sonia Leadmon, BS, William Tse, Aaron Cumpston, PharmD, Laura Gibson, PhD, Scot Remick, MD, FACP, Jame Abraham, MD, FACP, Michael Craig, MD, Sayed Mehdi Hamadani, MD

Blood (2010) 116 (21): 1347.

https://doi.org/10.1182/blood.V116.21.1347.1347

Published: 2010

Journal Articles

Higher Infused CD34+ Cell Dose Improves Survival In Patients Undergoing In Vivo T-Cell Depleted, but Not T-Cell Replete Peripheral Blood Hematopoietic Cell Transplant

Abraham S Kanate, MD, Salman Osman, MD, Aaron Cumpston, PharmD, Gerry Hobbs, PhD, Sonia Leadmon, BS, Pamela Bunner, BS, Kathy Watkins, MT, Laura Gibson, PhD, William Tse, MD, Jame Abraham, MD, FACP, Scot Remick, MD, FACP, Michael Craig, MD, Sayed Mehdi Hamadani, MD

Blood (2010) 116 (21): 1272.

https://doi.org/10.1182/blood.V116.21.1272.1272

Published: 2010

Journal Articles

In Vivo T-Cell Depletion Does Not Improve Rates of Graft-Versus-Host Disease and Transplantation Outcomes In Patients Undergoing Peripheral Blood Hematopoietic Cell Transplant.

Abraham S Kanate, MD, Salman Osman, MD, Aaron Cumpston, PharmD, Gerry Hobbs, PhD, Sonia Leadmon, BS, Pamela Bunner, BS, Laura Gibson, PhD, William Tse, MD, Jame Abraham, MD, FACP, Scot Remick, MD, FACP, Michael Craig, MD, Sayed Mehdi Hamadani, MD

Blood (2010) 116 (21): 4536.

https://doi.org/10.1182/blood.V116.21.4536.4536

Published: 2010

Journal Articles

Effect of T-Cell Dose On Outcomes After Peripheral Blood Allogeneic Hematopoietic Cell Transplantation in Hematological Malignancies.

Abraham S Kanate, MD, Farhad Khimani, MD, Aaron Cumpston, PharmD, Kathy Watkins, BS, Sonia Leadmon, BS, Michael D Craig, MD

Blood (2009) 114 (22): 1171.

https://doi.org/10.1182/blood.V114.22.1171.1171

Published: 2009

NARROW

Cost and Efficacy of Upfront Plerixafor Versus a “Just-in-Time” (JIT) Approach in Hematopoietic Progenitor Cell (HPC) Mobilization

Predictors and Impact Of 30-Day Readmissions On Patient Outcomes and Healthcare Costs After Allogeneic Hematopoietic Cell Transplantation

Intermediate-Dose Cyclophosphamide Versus Plerixafor and Granulocyte Colony Stimulating Factor (G-CSF) for Peripheral Blood Progenitor Cell (PBPC) Mobilization in Patients with Multiple Myeloma (MM) Treated with Novel Induction Chemotherapies – A Multicenter Analysis

Intermediate- Versus Low-Dose Cyclophosphamide and Granulocyte Colony Stimulating Factor for Peripheral Blood Progenitor Cell Mobilization in Patients with Multiple Myeloma Treated with Novel Induction Chemotherapies – A Multicenter Analysis

Response to Induction Chemotherapy with Novel Agents Does Not Predict Outcomes of Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation

Higher Infused CD34+ Cell Dose Improves Survival In Patients Undergoing In Vivo T-Cell Depleted, but Not T-Cell Replete Peripheral Blood Hematopoietic Cell Transplant

In Vivo T-Cell Depletion Does Not Improve Rates of Graft-Versus-Host Disease and Transplantation Outcomes In Patients Undergoing Peripheral Blood Hematopoietic Cell Transplant.

Effect of T-Cell Dose On Outcomes After Peripheral Blood Allogeneic Hematopoietic Cell Transplantation in Hematological Malignancies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only